2024-10-15 2025-10-31 false No description of principal activity Capium Accounts Production 1.1 16020127 2024-10-15 2025-10-31 16020127 bus:FullAccounts 2024-10-15 2025-10-31 16020127 bus:Micro-entities 2024-10-15 2025-10-31 16020127 bus:AuditExempt-NoAccountantsReport 2024-10-15 2025-10-31 16020127 bus:SmallCompaniesRegimeForAccounts 2024-10-15 2025-10-31 16020127 bus:PrivateLimitedCompanyLtd 2024-10-15 2025-10-31 16020127 2024-10-15 2025-10-31 16020127 2025-10-31 16020127 bus:RegisteredOffice 2024-10-15 2025-10-31 16020127 core:WithinOneYear 2025-10-31 16020127 core:AfterOneYear 2025-10-31 16020127 1 2024-10-15 2025-10-31 16020127 bus:Director1 2024-10-15 2025-10-31 16020127 bus:Director1 2025-10-31 16020127 2023-10-15 16020127 bus:LeadAgentIfApplicable 2024-10-15 2025-10-31 16020127 2024-10-14 16020127 bus:OrdinaryShareClass1 2024-10-15 2025-10-31 16020127 bus:OrdinaryShareClass1 2025-10-31 16020127 core:CostValuation core:Non-currentFinancialInstruments 2025-10-31 16020127 core:CostValuation core:Non-currentFinancialInstruments 2024-10-14 16020127 core:AdditionsToInvestments core:Non-currentFinancialInstruments 2025-10-31 16020127 core:DisposalsDecreaseInInvestments core:Non-currentFinancialInstruments 2025-10-31 16020127 core:RevaluationsIncreaseDecreaseInInvestments core:Non-currentFinancialInstruments 2025-10-31 16020127 core:Non-currentFinancialInstruments 2025-10-31 16020127 core:Non-currentFinancialInstruments 2024-10-14 iso4217:GBP xbrli:shares xbrli:pure

Registered Number: 16020127
England and Wales
PURA PHARMACEUTICALS L LTD
Unaudited Financial Statements
Period of accounts Start date: 15 October 2024 End date: 31 October 2025

PURA PHARMACEUTICALS L LTD Contents Page For the Period 15 October 2024 to 31 October 2025
Company Information | 1
Income Statement | 2
Statement of Financial Position | 3

PURA PHARMACEUTICALS L LTD Company Information For the Period 15 October 2024 to 31 October 2025
Director | Mohammad Reza Ashkan-Nejad
Registered Number | 16020127
Registered Office | 12 THE RIDINGS LONDON ENGLAND W5 3BU
1

PURA PHARMACEUTICALS L LTD Income Statement For the Period 15 October 2024 to 31 October 2025
|  | 2025 £
--- | --- | ---
Turnover |  | 4,270
Other charges |  | (2,243)
Tax |  | (385)
Profit/(Loss) for the financial period |  | 1,642
2

PURA PHARMACEUTICALS L LTD Statement of Financial Position As at 31 October 2025
|  | 2025
--- | --- | ---
|  | £ | £
Current assets |  | 3,372 |
Creditors: amount falling due within one year |  | (1,729) |
Net current assets |  |  | 1,643
Total assets less current liabilities |  |  | 1,643
Net assets |  |  | 1,643
Capital and reserves |  |  | 1,643
NOTES TO THE ACCOUNTS General Information PURA PHARMACEUTICALS L LTD is a private company, limited by shares, registered in England and Wales, registration number 16020127, registration address 12 THE RIDINGS, LONDON ENGLAND, W5 3BU. The presentation currency is £ sterling.
1. | Accounting policies Significant accounting policies Statement of compliance These financial statements have been prepared in compliance with FRS 105 – The Financial Reporting Standard applicable in the UK and Republic of Ireland and the Companies Act 2006. Basis of preparation The financial statements have been prepared under the historical cost convention. The financial statements are prepared in sterling which is the functional currency of the company.
2. | Average number of employees Average number of employees during the period was 0.
For the period ended 31 October 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies. Director's responsibilities: The members have not required the company to obtain an audit of its accounts for the period in question in accordance with section 476. The director acknowledges their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of accounts. These accounts have been prepared in accordance with the micro-entity provisions and FRS 105, the Financial Reporting Standard applicable to the micro-entities regime. The accounts have been delivered in accordance with the provisions applicable to companies subject to the small companies regime. The income statement has not been delivered to the Registrar of Companies. The financial statements were approved by the director on 02 July 2026 and were signed by:
-------------------------------- Mohammad Reza Ashkan-Nejad Director
3